> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Warns 4 Online GLP-1 Sellers
- URL: https://www.fdaweb.com/fda-warns-4-online-glp-1-sellers/
- Published: 2025-01-03T12:00:00.000Z
- Updated: 2026-09-14T14:49:57.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158401

FDA has sent Warning Letters to [Xcel Peptides](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024?ref=fdaweb.com), [Swisschems](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/swisschems-695663-12102024?ref=fdaweb.com), [Summit Research](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024?ref=fdaweb.com), and [Prime Peptides](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-vitality-inc-dba-prime-peptides-695156-12102024?ref=fdaweb.com) for introducing unapproved semaglutide (Nova Nordisk’s Ozempic and Wegovy), tirzepatide (Lilly’s Zepbound), and/or retatrutide (experimental Lilly drug) products into interstate commerce. The agency said its review of the companies’ Web sites and social media pages indicated the products were being marketed for human use despite being labeled for research purposes only.

The companies were told to respond with a list of specific steps they have taken to correct the violations and prevent their recurrence.